Gene therapy clinical progress creating paradigm shift — delandistrogene moxeparvovec (SRP9001/Eteplirsen GT) and other AAV-based gene therapy approaches — delivering functional dystrophin gene directly into muscle tissue enabling sustained dystrophin expression without repeated antisense oligonucleotide administration — representing fundamentally different therapeutic...